查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712541

全球胃癌治療市場 - 2025-2033

Global Gastric Cancer Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年全球胃癌治療市場規模達58.2億美元，預計2033年將達到146.6億美元，2025-2033年預測期內的複合年成長率為10.9%。

胃癌，也稱為胃癌，是指始於胃內壁細胞的一種癌症。它是世界上最常見和最致命的癌症之一，在東亞、歐洲和南美洲部分地區尤其常見。胃癌可以在胃的任何部位發展，並可能擴散到其他器官，如食道、胰臟、肝臟和淋巴結。

胃癌主要起源於胃壁上皮細胞，導致腺癌，這是最常見的胃癌類型（約佔 90-95％ 的病例）。然而，胃癌也包括其他較為罕見的形式，如淋巴瘤（淋巴組織癌）、胃腸道間質瘤（GIST）和神經內分泌腫瘤。

市場動態：

駕駛員和約束裝置

標靶治療的不斷進步顯著推動了胃癌治療市場的成長

胃癌治療中最顯著的進步之一是 HER2 標靶療法的開發。 HER2（人類表皮生長因子受體 2）是一種在某些胃癌細胞中過度表現的蛋白質，導致細胞生長不受控制。曲妥珠單抗（赫賽汀）是一種針對 HER2 的單株抗體，是 HER2 陽性胃癌的突破性治療方法。這種治療方法的成功使得它與化療聯合治療晚期胃癌被廣泛使用。

例如，2024年10月，安斯泰來製藥公司宣布，美國食品藥品監督管理局（FDA）批准VYLOY（zolbetuximab-clzb）聯合含氟嘧啶和鉑類化療，用於一線治療局部晚期不可切除或轉移性人表皮生長因子受體2（HER2）陰性胃腺癌或胃食管連接部（CLGEFDA）檢測VYLOY 是美國首個也是唯一一個核准的 CLDN18.2 標靶療法

標靶治療的不斷進步成為胃癌治療市場成長的重要動力。朝向更個人化和有效的治療轉變，加上 FDA 對新藥的批准、不斷成長的市場接受度以及患者存活率的提高，都促進了這一成長。隨著該領域研究的不斷深入，預計標靶治療將更加精細化，為胃癌患者帶來更大的希望，市場規模也將進一步擴大。

與治療相關的副作用和安全問題阻礙了市場的成長

儘管胃癌治療取得了重大進展，但副作用和安全問題仍然是疾病管理的重大挑戰。傳統療法和標靶療法的不良反應常常使患者不願遵守規定的治療方案，影響他們的生活品質，並使治療方案複雜化。這些擔憂反過來又阻礙了胃癌治療市場的廣泛應用和成長。

化療仍然是胃癌治療的基石，但它會帶來一系列嚴重的副作用。這些可能導致劑量減少、治療停止和生活品質下降，最終阻礙市場成長。雖然標靶治療和免疫療法徹底改變了胃癌治療，但這些療法並非沒有風險。儘管它們的副作用往往比化療少，但它們仍然可能導致嚴重的免疫相關不良事件（irAE）或脫靶效應。

流行病學分析

胃癌的發生率呈上升趨勢。根據DataM情報估計，2024年全球患病人數預計將接近102萬，其中亞太地區患病人數最多，達1.9028億。透過篩檢進行早期發現、更好的治療選擇以及改善的公共衛生措施促使已開發國家的發病率和死亡率下降。然而，胃癌仍然是一個沉重的醫療負擔，特別是在發展中國家和高風險族群。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 癌症類型片段
  • 按治療類型分類
  • 依給藥途徑分類
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 標靶治療的進展
      • 擴大臨床試驗和研究投資
    • 限制
      • 副作用和安全問題
      • 治療費用高昂
    • 機會
      • 治療方案的進展
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大行銷品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 管道分析
  • 流行病學分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：胃癌治療市場（依癌症類型）

  • 非賁門（遠端）胃癌
  • 近端胃癌
  • 瀰漫性胃癌
  • 淋巴瘤
  • 胃腸道間質瘤
  • 類癌腫瘤
  • 腺癌
  • 其他

第6章：胃癌治療市場（依治療類型）

  • 化療
    • 卡培他濱
    • 順鉑
    • 多西他賽
    • 阿黴素
    • 表柔比星
    • 氟尿嘧啶（5-FU）
    • 伊立替康
    • 亞葉酸鈣
    • 奧沙利鉑
    • 紫杉醇
    • 其他
  • 放射治療
  • 標靶治療
    • 雷莫蘆單抗
    • 瑞戈非尼
    • 曲妥珠單抗
    • 佐貝妥昔單抗
    • 其他
  • 免疫療法
    • 納武單抗
    • 帕博利珠單抗
  • 手術
    • 胃切除術
    • 胃空腸吻合術
    • 其他
  • 其他

第7章：胃癌​​治療市場（依給藥途徑）

  • 注射劑
  • 口服

第8章：胃癌治療市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Merck & Co., Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Eli Lilly and Company
  • Genentech USA, Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Blueprint Medicines Corporation
  • Daiichi Sankyo, Inc.
  • BeiGene, Ltd.
  • Ipsen Biopharmaceuticals Inc.
  • Taiho Oncology, Inc.
  • Deciphera Pharmaceuticals, LLC.

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: PH9517

The global gastric cancer treatment market size reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.66 billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Gastric cancer, also known as stomach cancer, refers to a type of cancer that begins in the cells lining the stomach. It is one of the most common and deadly forms of cancer worldwide, particularly prevalent in East Asia, Europe, and parts of South America. Gastric cancer can develop in any part of the stomach and may spread to other organs, such as the esophagus, pancreas, liver, and lymph nodes.

Gastric cancer primarily originates from the epithelial cells that line the stomach, leading to adenocarcinoma, which is the most common type of gastric cancer (around 90-95% of cases). However, gastric cancer can also include other, rarer forms such as lymphoma (cancer of lymphatic tissue), gastrointestinal stromal tumors (GISTs), and neuroendocrine tumors.

Market Dynamics: Drivers & Restraints

Rising advancements in targeted therapies are significantly driving the gastric cancer treatment market growth

One of the most notable advancements in gastric cancer treatment has been the development of HER2-targeted therapies. HER2 (human epidermal growth factor receptor 2) is a protein overexpressed in some gastric cancer cells, leading to uncontrolled cell growth. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, has been a groundbreaking treatment for HER2-positive gastric cancer. The success of this treatment has led to its widespread use in combination with chemotherapy for advanced gastric cancer.

For instance, in October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test. VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.

The rising advancements in targeted therapies have been a significant driver for the growth of the gastric cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for gastric cancer patients and expanding the market further.

Side effects and safety concerns associated with the treatment are hampering the market growth

Despite the significant advancements in gastric cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. The adverse effects associated with both traditional and targeted therapies often deter patients from adhering to prescribed regimens, impact their quality of life, and complicate treatment regimens. These concerns, in turn, hinder the widespread adoption and growth of the gastric cancer treatment market.

Chemotherapy remains a cornerstone of treatment for gastric cancer, but it is associated with a range of severe side effects. These can lead to dose reductions, discontinuation of therapy, and decreased quality of life, which ultimately hampers market growth. While targeted therapies and immunotherapies have revolutionized gastric cancer treatment, these therapies are not without their risks. Although they tend to have fewer side effects than chemotherapy, they can still cause severe immune-related adverse events (irAEs) or off-target effects.

Epidemiology Analysis

The incidence of gastric cancer is rising. As per DataM intelligence estimates, nearly 1.02 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 190.28 million cases. Early detection through screening, better treatment options, and improved public health measures have contributed to the decline in incidence and mortality rates in developed countries. However, gastric cancer continues to present a major healthcare burden, particularly in developing nations and among high-risk populations.

Segment Analysis

The global gastric cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.

Treatment Type:

The chemotherapy segment is expected to dominate the gastric cancer treatment market with the highest market share

Chemotherapy is frequently used as the primary treatment in advanced gastric cancer, often in combination with targeted therapies or immunotherapy. In cases where surgery is not possible, chemotherapy serves as a crucial palliative treatment to control symptoms, slow the disease's progression, and improve survival rates. For instance, FOLFOX (a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin) is a standard chemotherapy regimen used in gastric cancer. This regimen is particularly effective for advanced gastric cancer and has been widely adopted.

Chemotherapy is frequently combined with targeted therapies like trastuzumab, ramucirumab, and nivolumab to enhance efficacy, especially in advanced or metastatic gastric cancer. These combination regimens have become the standard of care in many treatment protocols. The growing trend of combining chemotherapy with newer therapies has expanded its market dominance, as it remains the central component of first-line and second-line treatment regimens in both HER2-positive and HER2-negative gastric cancers.

Geographical Analysis

North America is expected to hold a significant position in the global gastric cancer treatment market with the highest market share

The FDA (U.S. Food and Drug Administration) and Health Canada are at the forefront of regulatory approvals for new cancer therapies, including those for gastric cancer. These agencies have fast-tracked and drug approvals for novel treatments like TEVIMBRA (tislelizumab-jsgr), nivolumab (Opdivo), trastuzumab (Herceptin), and ramucirumab (Cyramza). This further accelerates the market growth in the region with various effective treatments.

For instance, in December 2024, BeiGene, Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (>=1).

North America has been a leader in adopting targeted therapies and immunotherapies, which are increasingly used to treat gastric cancer. The region's healthcare system supports the use of expensive, but highly effective, biologics and immunotherapy drugs that target specific proteins or immune checkpoints involved in cancer progression. For instance, Trastuzumab (Herceptin) is widely used for HER2-positive gastric cancer, and its combination with chemotherapy has led to better survival rates. Nivolumab (Opdivo), an immune checkpoint inhibitor, is also approved for use in gastric cancer and has been shown to significantly improve survival in combination with chemotherapy.

Competitive Landscape

Top companies in the gastric cancer treatment market include Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC., and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global gastric cancer treatment market report delivers a detailed analysis with 68 key tables, more than 61 visually impactful figures and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Cancer Type
  • 2.4. Snippet by Treatment Type
  • 2.5. Snippet by Route of Administration
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Targeted Therapies
      • 3.1.1.2. Expanding Clinical Trials and Research Investment
    • 3.1.2. Restraints
      • 3.1.2.1. Side Effects and Safety Concerns
      • 3.1.2.2. High Treatment Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Advancements in Treatment Options
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. Latin America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Pipeline Analysis
  • 4.9. Epidemiology Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Gastric Cancer Treatment Market, By Cancer Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 5.1.2. Market Attractiveness Index, By Cancer Type
  • 5.2. Non-Cardia (Distal) Stomach Cancer*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Proximal Stomach Cancer
  • 5.4. Diffuse Stomach Cancer
  • 5.5. Lymphomas
  • 5.6. Gastrointestinal Stromal Tumors
  • 5.7. Carcinoid Tumors
  • 5.8. Adenocarcinoma
  • 5.9. Others

6. Gastric Cancer Treatment Market, By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Chemotherapy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Capecitabine
    • 6.2.4. Cisplatin
    • 6.2.5. Docetaxel
    • 6.2.6. Doxorubicin
    • 6.2.7. Epirubicin
    • 6.2.8. Fluorouracil (5-FU)
    • 6.2.9. Irinotecan
    • 6.2.10. Leucovorin
    • 6.2.11. Oxaliplatin
    • 6.2.12. Paclitaxel
    • 6.2.13. Others
  • 6.3. Radiation Therapy
  • 6.4. Targeted Therapy
    • 6.4.1. Ramucirumab
    • 6.4.2. Regorafenib
    • 6.4.3. Trastuzumab
    • 6.4.4. Zolbetuximab
    • 6.4.5. Others
  • 6.5. Immunotherapy
    • 6.5.1. Nivolumab
    • 6.5.2. Pembrolizumab
  • 6.6. Surgery
    • 6.6.1. Gastrectomy
    • 6.6.2. Gastrojejunostomy
    • 6.6.3. Others
  • 6.7. Others

7. Gastric Cancer Treatment Market, By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Injectable*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Oral

8. Gastric Cancer Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. China
      • 8.4.6.2. India
      • 8.4.6.3. Japan
      • 8.4.6.4. South Korea
      • 8.4.6.5. Rest of Asia-Pacific
  • 8.5. South America
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. Brazil
      • 8.5.6.2. Argentina
      • 8.5.6.3. Rest of South America
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Merck & Co., Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Eli Lilly and Company
  • 10.3. Genentech USA, Inc.
  • 10.4. Pfizer Inc.
  • 10.5. Astellas Pharma Inc.
  • 10.6. Bristol-Myers Squibb Company
  • 10.7. Blueprint Medicines Corporation
  • 10.8. Daiichi Sankyo, Inc.
  • 10.9. BeiGene, Ltd.
  • 10.10. Ipsen Biopharmaceuticals Inc.
  • 10.11. Taiho Oncology, Inc.
  • 10.12. Deciphera Pharmaceuticals, LLC.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us